12:00 AM
Jul 16, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

TOBI Podhaler regulatory update

FDA's Anti-Infectives Drugs Advisory Committee will meet on Sept. 5 to discuss an NDA from Novartis for TOBI Podhaler to treat Pseudomonas aeruginosa...

Read the full 95 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >